Nektar's opioid painkiller succeeds in key late-stage study

(Reuters) - Nektar Therapeutics said its experimental opioid, designed to achieve pain relief minus the high levels of euphoria that can lead to abuse and addiction with existing opioids, succeeded in a key late-stage study.